Clinical Studies with Budotitane — A New Non-Platinum Metal Complex for Cancer Therapy

  • Manfred E. Heim
  • Henning Flechtner
  • Bernhard K. Keppler
Part of the Progress in Clinical Biochemistry and Medicine book series (PCBM, volume 10)

Abstract

The new antitumor-active transition metal complex diethoxybis(1-phenylbutane-1,3-dionato)tita- nium(IV) (INN Budotitane, DBT) has demonstrated antitumor activity in several experimental tumor models. The cytotoxic activity of DBT in the AMMN-induced autochthonous colorectal carcinoma in the rat appeared especially promising. In the preclinical toxicity studies, liver toxicity, mild nephrotoxicity, but no myelosuppression was observed.

Keywords

Titanium Toxicity Zirconium Leukemia Creatinine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Prestayko AW, Crooke ST, Carter SK (eds) (1980) Cisplatin — current status and new develop-ments. Academic Press, Inc. New YorkGoogle Scholar
  2. 2.
    Slavik M, Blanc O, Davis J (1983) Spirogermanium: A new investigational drug of novel structure and lack of bone marrow toxicity. Invest New Drugs 1: 225PubMedGoogle Scholar
  3. 3.
    Miyao K, Onishi T, Asai K, Tomizawa S, Suzuki F (1980) Toxicology and phase I studies on a novel organogermanium. compound, Ge-132. In: Current chemotherapy and infectious disease, Vol II. Nelson JD, Grassi C (eds) The American Society for Microbiology: Washington, pp 1527Google Scholar
  4. 4.
    Hopkins SJ (1981) Gallium Nitrate. Drugs of the Future IV: 228Google Scholar
  5. 5.
    Keller HJ, Keppler BK, Schmähl D (1982) Antitumor activity of cis-dihalogenobis(1-phenyl-1, 3-butane-dionato)titanium(IV) compounds against Walker 256 carcinosarcoma. Arznei-Forsch/ Drug Res 32 (11) 8: 806Google Scholar
  6. 6.
    Keppler BK, Heim ME (1988) Antitumor-active bis -β-diketonato metal complexes: budotitane — a new anticancer agent. Drugs of the Future 13: 637Google Scholar
  7. 7.
    Keppler BK, Michels K (1985) Antitumor activity of 1,3-diketonato zirconium(IV) and hafnium- (IV) complexes. Arzneim-Forsch/Drug Res 35 (II) 12: 1837Google Scholar
  8. 8.
    Keppler BK, Schmähl D (1986) Preclinical evaluation of dichlorobis(l-phenylbutane-l,3-dionato)- titanium(IV) and budotitane. Arzneim-Forsch/Drug Res 36 (II) 12: 1822Google Scholar
  9. 9.
    Bischoff H, Berger MR, Keppler BK, Schmähl D (1987) Efficacy of β-diketonato complexes of titanium, zirconium, and hafnium against chemically induced autochthonous colonic tumors in rats. J Cancer Res Clin Oncol 113: 446PubMedCrossRefGoogle Scholar
  10. 10.
    Keppler BK, Heim ME, Flechtner H, Wingen F, Pool BL (in press) Antitumor activity of budoti-tane in three different transplantable tumor systems, its mutagenicity, and first results of clinical phase I studies. Drug ResGoogle Scholar
  11. 11.
    EORTC New Drug Development Commitee (1985) EORTC guidelines for phase I trials with single agents in adults. Eur J Cancer Clin Oncol 21: 1005CrossRefGoogle Scholar
  12. 12.
    WHO Handbook for reporting results of cancer treatment (1979) WHO publication No 48, GenevaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • Manfred E. Heim
    • 1
  • Henning Flechtner
    • 1
  • Bernhard K. Keppler
    • 2
  1. 1.Onkologisches Zentrum, Klinikum MannheimUniversität HeidelbergMannheimGermany
  2. 2.Anorganisch-Chemisches Institut der Universität HeidelbergHeidelbergGermany

Personalised recommendations